BioVaxys Technology Corp. C.BIOV

Collaborations/Grants/Government/Licensees

[frankman]

Collaborations
•    BioVaxys and a research team at Dalhousie University are currently in research discussions on using DPX to package/deliver multiple neoantigens for undisclosed tumor types.  Through December, both parties are working on designing potential study protocols. 

•    BioVaxys has been invited by CEPI (the Coalition for Epidemic Preparedness Innovations) to present on the DPX platform in infectious disease applications---this presentation to a screening team at CEPI is the principal entry process for a funded collaboration.   
https://cepi.net/

CEPI is a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats.  CEPI’s programs aim to substantially reduce global epidemic and pandemic risk. CEPI’s priority diseases include Influenza, Chikungunya, COVID-19, Ebola, Lassa Fever, MERS, Nipah, Rift Valley Fever, and novel viral threats with epidemic or pandemic potential (also known as “Disease X”) by supporting development of cutting-edge technologies that can accelerate the development of safe, effective and accessible vaccines against emerging disease outbreaks.  CEPI was founded by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome Foundation, and the World Economic Forum specifically to fund promising vaccine programs.  Our presentation will likely be in January 2025. 

•    A third party has made a personal introduction of BioVaxys to C-level management of a $1,278M global animal health company that develops, manufactures and markets a broad range of veterinary products for farm and companion animal species.  This has led to this animal health company tasking their business development team to evaluate the DPX opportunity for current and pipeline products; further clarity on the type of relationship we could be looking at will come with the continuing discussions over the next few weeks. 

•    The BARDA / RRPV solicitation for influenza has been extended to end of January 2025.  BioVaxys is looking for RRPV partners with mRNA or peptide influenza antigens for a joint BARDA program proposal.
https://www.rrpv.org/

Grants/Government
•    BioVaxys has entered into an agreement with Leyton Canada Inc., to identify, prepare, and submit a grant proposal to the National Institutes of Health (NIH) for funding the Company’s DPX-based peanut allergy vaccine program.  Grant funding, if awarded, can be used to retroactively pay project-related costs.  Leyton Canada is a leading global business advisory firm with one of its major focuses on successfully obtaining federal grant funding.
https://leyton.com/ca/en/

•    The National Research Council of Canada is currently working with BioVaxys to identify and introduce the Company to re3searecher in the mRNA field for potential collaborations.

Licensees
•    BioVaxys and SpayVac for Wildlife, Inc. jointly announced that SpayVac for Wildlife, Inc.’s Madison, Wisconsin laboratory and production facility is now fully able to supply its cutting-edge contraceptive vaccines, including its well-established pZP vaccine (“SpayVac®”) and its newest GnRH vaccine for commercial aquaculture and other species.
The scaled-up production capacity will support wider SpayVac availability for field trials and market seeding studies, the production ramp-up in preparation for a SpayVac launch in the near future, as well as new antigen formulations tailored for diverse animal contraceptive needs.  The ability to produce two different lines of vaccine is a significant advancement following SpayVac for Wildlife’s recent announcement of completing the set-up of its Madison-based research and production facility.  Part of our use of proceeds from SpayVac’s ongoing fundraising will be to further scale up so they can produce tens of thousands of vaccines.
Recently, large-scale shipments were made by SpayVac for Wildlife to support a major feral horse population management project in Europe, underscoring their commitment to expanding animal population control efforts globally.  This follows the production of vaccine for an immunocontraception project in Southeast Asia this past summer.
SpayVac continues to build momentum with ongoing trials in collaboration with the U.S. government and the EU, as well as a prominent aquaculture genetics company, focusing on a potential alternative to induced triploidy, which results in sterility but leaves fish more susceptible to disease.
 

[Hideaway]

A very impressive NR outlining numerous opportunities for BIOV. I hope they can persuade a few of the firms, governments,universities and potential partners to to participate  and fund activities as they are not flush with cash. IMV had good results with the phase 11 clinical trials for DLBCL as well as for ovarian cancer..Unfortunately,Merck dropped out from funding the trials for DLBCL in